🇺🇸 FDA

Intelligence · Clinical Pipeline

Teva Pharma Pipeline

All ClinicalTrials.gov programs at Teva Pharma — phase, modality, and trial IDs.

Programs
473

Quick answer

Teva Pharma has 473 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. TP-38

    Teva Pharma GmbH

    Glioblastoma Multiforme

    phase 2 small molecule completed

    1 trial

  2. TV-1380 150 mg

    Teva Pharma GmbH

    Cocaine Addiction

    phase 2 small molecule completed

    1 trial

  3. TV-45070

    Teva Pharma GmbH

    Osteoarthritis of the Knee

    phase 2 small molecule completed

    1 trial

  4. TV-45070

    Teva Pharma GmbH

    Postherpetic Neuralgia

    phase 2 small molecule completed

    1 trial

  5. Talampanel

    Teva Pharma GmbH

    Epilepsy

    phase 2 small molecule completed

    1 trial

  6. Talampanel

    Teva Pharma GmbH

    ALS

    phase 2 small molecule completed

    1 trial

  7. Talampanel

    Teva Pharma GmbH

    Amyotrophic Lateral Sclerosis

    phase 2 small molecule terminated

    1 trial

  8. Talampanel

    Teva Pharma GmbH

    Glioblastoma Multiforme

    phase 2 small molecule terminated

    2 trials

  9. Tiotropium HFA BAI 4.5 mcg

    Teva Pharma GmbH

    COPD

    phase 2 small molecule completed

    1 trial

  10. Tiotropium HFA BAI 5 mcg

    Teva Pharma GmbH

    Chronic Obstructive Pulmonary Disease

    phase 2 small molecule terminated

    1 trial

  11. Tizanidine (sublingual or oral)

    Teva Pharma GmbH

    Muscle Spasticity

    phase 2 small molecule completed

    1 trial

  12. armodafinil

    Teva Pharma GmbH

    Schizophrenia

    phase 2 small molecule completed

    2 trials

  13. autologous mesenchymal stem cells implantation

    Teva Pharma GmbH

    Tibial Fracture

    phase 2 other completed

    1 trial

  14. bendamustine

    Teva Pharma GmbH

    Hodgkin Lymphoma

    phase 2 small molecule active

    2 trials

  15. bendamustine

    Teva Pharma GmbH

    Multiple Myeloma

    phase 2 small molecule completed

    1 trial

  16. bendamustine and rituximab

    Teva Pharma GmbH

    Non-Hodgkin's Lymphoma

    phase 2 small molecule completed

    1 trial

  17. cytarabine

    Teva Pharma GmbH

    Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome

    phase 2 small molecule terminated

    1 trial

  18. desogestrel/ethinyl estradiol and ethinyl estradiol

    Teva Pharma GmbH

    Hemostasis

    phase 2 small molecule completed

    1 trial

  19. edratide

    Teva Pharma GmbH

    Systemic Lupus Erythematosus

    phase 2 small molecule terminated

    1 trial

  20. etiprednol dicloacetate

    Teva Pharma GmbH

    Crohn's Disease

    phase 2 small molecule completed

    1 trial

  21. fremanezumab

    Teva Pharma GmbH

    Interstitial Cystitis

    phase 2 small molecule terminated

    1 trial

  22. glatiramer acetate

    Teva Pharma GmbH

    Crohns Disease

    phase 2 small molecule active

    1 trial

  23. glatiramer acetate 20 mg

    Teva Pharma GmbH

    Relapse-Remitting Multiple Sclerosis

    phase 2 small molecule completed

    1 trial

  24. glatiramer acetate 20 mg

    Teva Pharma GmbH

    Relapsing Remitting Multiple Sclerosis

    phase 2 small molecule completed

    1 trial

  25. glatiramer acetate with minocycline

    Teva Pharma GmbH

    Relapse Remitting Multiple Sclerosis

    phase 2 small molecule completed

    1 trial

  26. infusion of MYOCET

    Teva Pharma GmbH

    Cerebral Lymphoma B Cell Refractory

    phase 2 small molecule terminated

    1 trial

  27. inhaled delta-8-THC 300mcg or 600mcg per dose

    Teva Pharma GmbH

    Cancer

    phase 2 small molecule terminated

    1 trial

  28. laquinimod 0.3

    Teva Pharma GmbH

    Relapsing Remitting Multiple Sclerosis

    phase 2 small molecule completed

    1 trial

  29. lestaurtinib

    Teva Pharma GmbH

    Polycythemia Vera

    phase 2 small molecule completed

    1 trial

  30. methylprednisolone

    Teva Pharma GmbH

    Multiple Sclerosis (MS)

    phase 2 small molecule terminated

    1 trial

  31. rasagiline mesylate

    Teva Pharma GmbH

    Multiple System Atrophy

    phase 2 small molecule completed

    1 trial

  32. sublingual tizanidine 12 mg

    Teva Pharma GmbH

    Spasticity

    phase 2 small molecule terminated

    1 trial

  33. talampanel

    Teva Pharma GmbH

    Dyskinesias

    phase 2 small molecule completed

    1 trial

  34. tbo-filgrastim

    Teva Pharma GmbH

    Neutropenia

    phase 2 small molecule completed

    1 trial

  35. 45-mg hydrocodone bitartrate extended-release tablet (crushed or intact)

    Teva Pharma GmbH

    Drug Abuse

    phase 1 small molecule completed

    1 trial

  36. 5 mg/500 mg Glipizide Metformin Hydrochloride Tablets

    Teva Pharma GmbH

    Healthy

    phase 1 small molecule completed

    1 trial

  37. 5 mg/500 mg METAGLIP™ Tablets

    Teva Pharma GmbH

    Healthy

    phase 1 small molecule completed

    1 trial

  38. 600 mg Amoxicillin/42.9 mg Clavulanate Postassium /5 mL

    Teva Pharma GmbH

    Healthy

    phase 1 small molecule completed

    2 trials

  39. 90 mg dose of the hydrocodone bitartrate extended-release tablet administered as either two 45-mg tablets (Treatment A) or one 90-mg tablet (Treatment B).

    Teva Pharma GmbH

    Pain

    phase 1 small molecule completed

    1 trial

  40. A randomized, Phase 1b, single-center, observer-blind, active-controlled study to evaluate the safety, immunogenicity, and immunological mechanisms of one single administration of TETRALITE influenza vaccine at two dose levels of LiteVax Adjuvant, in healthy participants aged 60 years and older and in healthy participants aged 18 to 50 years.

    Teva Pharma GmbH

    Influenza

    phase 1 other active

    1 trial

  41. A randomized, Phase I, single-center, observer-blind, active-controlled study to evaluate the safety, tolerability and immunogenicity of one single administration of PCV-LITE, a novel adjuvanted pneumococcal conjugate vaccine at one dose level of LiteVax Adjuvant, in healthy participants aged 18-50 years.

    Teva Pharma GmbH

    Pneumococcal infection

    phase 1 other active

    1 trial

  42. ADASUVE®

    Teva Pharma GmbH

    BiPolar

    phase 1 small molecule completed

    1 trial

  43. ARAVA® 20 mg tablets

    Teva Pharma GmbH

    Healthy

    phase 1 small molecule completed

    1 trial

  44. Adapalene

    Teva Pharma GmbH

    Acne Vulgaris

    phase 1 small molecule completed

    1 trial

  45. Albuterol dry powder inhaler

    Teva Pharma GmbH

    Asthma

    phase 1 small molecule completed

    1 trial

  46. Alendronate Sodium Tablets 70mg

    Teva Pharma GmbH

    Healthy

    phase 1 small molecule completed

    1 trial

  47. Alprazolam Extended-Release 3 mg Tablets

    Teva Pharma GmbH

    Healthy

    phase 1 small molecule completed

    2 trials

  48. Amlodipine Besylate

    Teva Pharma GmbH

    Healthy

    phase 1 small molecule completed

    2 trials

Frequently asked questions

How many pipeline programs does Teva Pharma have?

473 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.